Clinical trial
A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
NCT04252846 is registered in ClinicalTrials.gov with Eisai Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Non-Interventional, Observational, Multicenter Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Adjunctive Therapy in the Routine Clinical Care of Subjects >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
- Lead sponsor
- Eisai Limited
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 20, 2020
- Completion date
- January 12, 2023
- Enrollment
- 191 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.
generalised tonic-clonic seizures, idiopathic generalized epilepsy, partial onset seizures